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Among the recent advances in the molecular targeted therapy of cancer, the applications focused on epidermal growth factor
receptor (EGFR) are currently the most promising and the most advanced at clinical level. In view of the different modes of action of
monoclonal antibodies and tyrosine kinase inhibitors (TKI), it is tempting to examine the effect of a combination between these two
EGFR targeting approaches. It was the purpose of the present study to test this combination at experimental level by using two
epidermoid human cell lines CAL 33 and CAL 39. As C225 (Cetuximab
s) and ZD1839 (Iressa
s) are, respectively, the most clinically
advanced drugs in the category of anti-EGFR drugs, the experiments were performed using these two representative compounds.
The combination of C225 and ZD1839 was antagonistic whatever the cell line considered. These antagonistic effects were
corroborated by molecular changes in apoptosis (PARP) and EGFR signalling (phospho-p42–44). Drugs alone led to a diminution in
EGFR levels, while their combination increased the cellular expression in EGFR. These data suggest that new and tempting treatment
strategies on the EGFR target consisting in a double hit with a monoclonal antibody and a TKI must be considered with caution.
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Epidermal growth factor receptor (EGFR) is a protein tyrosine
kinase which plays a crucial role in signal transduction pathways
that regulate key cellular functions such as survival and prolifera-
tion. Among the recent advances in the molecular targeted therapy
of cancer, the applications focused on EGFR are currently the most
promising and the most advanced at clinical level (Arteaga, 2001;
Baselga, 2001; Ciardiello and Tortora, 2001; Yarden, 2001;
Mendelsohn, 2002; Zwick et al, 2002). Considering the set of
therapeutic tools targeting EGFR (Modi and Seidman, 2002), there
are at present two well-identified emerging categories of drugs, the
one characterised by monoclonal antibodies (Mabs) and the other
by tyrosine kinase inhibitors (TKIs).
Mabs and TKIs clearly differ in their mode of action at target
level. The primary action mechanism of C225, a chimeric Mab, is a
competitive antagonism for EGFR. Independent of the phosphor-
ylation status of the receptor, the EGFR–C225 complex is
subsequently internalised (Fan et al, 1994; Prewett et al, 1996).
The outcome of the EGFR–C225 complex following internalisation
is not clearly documented, particularly regarding the stage between
degradation and cell membrane recycling of the intact receptor.
Tyrosine kinase inhibitors act on the cytosolic ATP-binding
domain of EGFR by inhibiting EGFR autophosphorylation.
Depending on the nature of the TKI, EGFR inhibition can be
either reversible, as with ZD839 or OSI-774, or irreversible, as for
instance with PD183805 (Noonberg and Benz, 2000; Ciardiello and
Tortora, 2001; Denny, 2002). The irreversibility of the inhibition is
due to covalent fixation of the drug at the ATP-binding site. In
contrast to the approach using Mabs, the use of TKIs is not strictly
specific for the ATP pocket of the EGFR; this can be explained by
the fact that TKIs are all ATP competitors at the ATP site of the
tyrosine kinases (Denny, 2002). Thus, for TKIs, some variable
crossreactivity may exist between EGFR and other HER-B family
members such as HER-2 (Arteaga, 2001).
In view of the different modes of action of Mabs and TKIs on
EGFR, it is tempting to examine the effect of a combination
between these two EGFR-targeting approaches. In addition, clinical
studies indicate that the pharmacodynamics of Mabs and TKIs are
not strictly superimposable with side effects as regards Mabs being
mainly centred on the skin and, regarding TKIs, mostly related to
the skin and to gastrointestinal intolerance (Thomas and Grandis,
2004). It was the purpose of the present study to test this
combination at the experimental level by using two epidermoid
human cell lines CAL 33 and CAL 39. As C225 (Cetuximab
s;
Herbst and Hong, 2002; Saltz et al, 2004) and ZD1839 (Iressa
s;
Ranson et al, 2002; Fukuoka et al, 2003) are, respectively, the most
clinically advanced drugs in the category of Mabs and TKIs, the
experiments were performed using these two representative
compounds. Along with an analysis of the drug impact on cell
proliferation, the present study included an examination of
drug effects on apoptotic pathway (phospho-AKT and PARP
cleavage), on MAP kinase pathway (phospho-MAPK) and on EGFR
expression.
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sMATERIALS AND METHODS
Chemicals
All chemicals were obtained from Sigma Chemicals (Saint Quentin
Fallavier, France) and were of the highest purity grade. DMEM and
glutamine were obtained from Biowhittaker (Verviers, Belgium)
and foetal bovine serum (FBS) from Dutscher (Brumath, France).
Drugs were kindly provided: Cetuximab
s (C225) by Merck
(Darmstadt, Germany) and Iressa
s (ZD1839) by Astra Zeneca
(Rueil Malmaison, France), respectively.
For ZD1839, a 50mM working solution in dimethylsulphoxide
(DMSO) was prepared before use. Radiochemicals,
3H-thymidine
and
125I-EGF, were provided by Amersham Biosciences (Orsay,
France).
Cell lines
One human head and neck cancer cell line CAL33 and one human
vulvar cancer cell line CAL39 were used in the present study.
Epidermal growth factor receptor levels (fmolmg
 1prot
 1) were
33800 and 6500 for CAL33 and CAL39, respectively (ligand-
binding assay as previously published by us; Olivier et al, 1990).
Both cell lines were maintained in DMEM supplemented with 10%
FBS, 2mM glutamine, 50000Ul
 1 penicillin and 80mM streptomy-
cin in a fully humidified incubator (Sanyo, Japan) at 371Ci na n
atmosphere containing 8% CO2.
Drug administration schedule
Drug effects were assessed using
3H-thymidine incorporation. We
checked whether this assay compared well with the viability results
obtained with the classical MTT test: the results were almost
superimposable for ZD1839; it was not the case for C225, which
exhibited acceptable dose–effect curves with the thymidine
incorporation only. Experiments were performed in DMEM
supplemented with 0.5% FBS. This low serum concentration was
selected so as to reduce the presence of exogenous growth factors
while ensuring a correct survival of cells without drug. Cells were
seeded on day 0 in a 24-well microplate, 18000 cells per well for
CAL33 and 24000 cells per well for CAL39. The cell seeding
concentrations were chosen to allow exponential growth through-
out the experiment. Drugs were added 48h after cell seeding and
applied during 96h either alone or in combination. The range of
drug concentrations was chosen according to the results of
preliminary experiments in order to obtain the most complete
single-agent dose–effect curves. Concentrations thus varied
between 10
 11 and 10
 7 M for C225 and between 10
 8 and 10
 4 M
for ZD1839. The assay method was essentially that described by
Volm et al. (1970): after the end of the drug incubation time, that
is, 120h after cell seeding, [
3H]dTHd was added (52CimM
 1; final
concentration, 3mCiml
 1) and incubation was continued for
another 2h. Plates were then cooled on ice. The experiments were
ended by adding ice-cold 5% trichloracetic acid (TCA) and the
wells were washed twice with TCA, then precipitated DNA was
dissolved in NaOH 10% solution and counted on a liquid
scintillation counter (Wallac, 1409 DSA). Results were expressed
as the percentage of radioactive incorporation relative to a control
without the drugs. Experiments were performed at distance in
triplicate.
Drug interaction analysis
Combination Index (CI) calculations The cytotoxic effects
obtained with the ZD1839/C225 combinations were analysed
according to the Chou and Talalay method (1984) on Calcusyn
software (Biosoft, Cambridge, UK). Interaction between
ZD1839 and C225 was assessed by means of an automatically
computed CI.
The use of the Chou and Talalay ‘CI’ requires a dose–effect
curve, which reaches the zero value for survival. This was not
strictly the case for the C225 dose–effect curve. For this reason, in
a complementary analysis, we replaced the CI by the following
ratio R:
R ¼
Survival½C225 þ ZD1839 
Survival½C225alone  survival½ZD1839alone 
for example, if C225 at a concentration [c] and ZD1839 at a
concentration [z] which, when given alone, have a 50% growth-
inhibitory effect and, when given together (at these same
concentrations, respectively, [c] and [z]), have a 75% effect, then
in this case R will be: (1–0.75)/0.5 0.5¼1.
Then, if Ro0.8, the association is considered to be synergistic
0:8oRo1:2; the association is considered to be additive
Ro1:2; the association is considered to be antagonistic
Molecular factors
All experiments concerning the following investigated molecular
factors were performed on CAL33 cells.
Epidermal growth factor receptor measurement by ligand-
binding assay
Epidermal growth factor receptor expression was assayed as
previously described by us (Olivier et al, 1990). Cells were grown to
80–90% confluence, in 24-well plates, in 10% FBS–DMEM at 371C.
Then drugs (ZD1839 2 10
 6 M, C225 10
 9 M final concentration)
were added and incubation was performed during 2 days. Cells
were rinsed three times with 500ml RPMI 1640 containing 0.1%
BSA at 2–41C and incubated for 30min with the same medium
(500ml per well) at 41C. Epidermal growth factor receptor content
was determined by incubation in RPMI medium for 3h at 41Ci n
the presence of increasing concentrations of
125I-EGF (0.01, 0.02,
0.04, 0.08, 0.12, 0.18, 0.2nM) and with 0.2nM of
125I-EGF with
increasing concentrations of unlabelled EGF (0.05, 0.1, 0.2, 0.4, 0.8,
1.6, 3.2, 6.4, 20, 200nM). Plates were put on ice to stop the reaction,
the supernatant was removed, and cells were washed twice with
PBS containing 0.1% BSA (41C, 500ml per well). Cells were
solubilised in 1 M NaOH at 371C (500ml per well for 30min).
Radioactivity was determined by gamma counting. The number of
receptor sites per cell (N) and the dissociation constant (Kd) were
determined by Scatchard analysis (each point on the Scatchard
plots was plotted in quadruplicate). Cell number was determined
in wells run in parallel, by resuspending cells in 200ml PBS at room
temperature and counting with a haemocytometer. Experiments
were performed at distance in duplicate.
Western blot analyses Cells were seeded in a 75cm
2 cell culture
flask for 48h in DMEMþ10% FBS medium. They were then
washed three times with PBS and incubated for another 48h in
DMEM medium without FBS in the presence of 2 10
 6 M ZD1839
and/or 1 10
 9 M C225 (concentrations at which drug maximum
effect on thymidine incorporation was obtained). Then, at the end
of drug exposure, serum (FBS, 10% final concentration) was added
and cell pellets were collected at t0 (before addition of serum) and
5 and 30min after addition of FBS. All cell pellets were stored at
 801C before analysis. Cell pellets collected at t0 were used for the
measurement of cleaved PARP and EGFR; those obtained at 5 and
30min were intended for the analysis of PAKT and Pp42–44. The
expression of EGFR, HER-2, cleaved PARP, PAKT, Pp42–44 was
measured using the Western blot technique. Briefly, equivalent
quantities of protein for each drug combination were separated on
a 12% SDS–polyacrylamide gel (EGFR and HER-2 excepted, for
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swhich a 7.5% polyacrylamide gel was used). After overnight
transfer to a membrane, the proteins were revealed: for PAKT, the
first antibody was rabbit polyclonal (Ozyme) 1/1000 in TBS 5%
BSA using Jurkat cells as a positive control. For Pp42–44, the first
antibody was of mouse origin kindly provided by CNRS Unit 6543
(Centre Antoine Lacassagne, Nice) 1/5000 in TBS 5% milk using
A431 as a positive control. For PARP, the first antibody was of
Rabbit origin (Ozyme) 1/1000 in TBS 5% milk. For EGFR, the first
antibody was the mouse monoclonal Ab12 (Neomarkers) 1/1000 in
TBS 5% milk using A431 as a positive control. After blotting with
an adapted second antibody, proteins were revealed in a darkroom
using ECL. All experiments were performed in triplicate.
RESULTS
The effects of C225, ZD1839 and their combinations are described
in Figures 1 and 2 for CAL33 and CAL39 cells, respectively. Of
note, and for both cell lines, C225 alone never led to 0% survival.
The dose–effect curves of the C225þZD1839 combination were
either just under (CAL 33 cells) or even clearly above (CAL39 cells)
the ZD1839 dose–effect curve. This direct observation suggests an
antagonistic interaction between the two drugs. The examination
of both R values and CIs confirmed that the combination of C225
and ZD1839 was antagonistic whatever the cell line considered
(Table 1).
The effects of C225, ZD1839 and their combination on PARP,
PAKT and Pp42–44 are depicted in Figure 3. The impact of
ZD1839 on PARP cleavage was more marked than that generated
by C225 alone (Figure 3A). Of note, when the two drugs were
combined, there was a smaller change in PARP as compared to the
change with ZD1839 alone. This finding is in agreement with the
data on cell survival indicating infra-additive cytotoxic effects
resulting from the association of the two anti-EGFR drugs. There
were no clear-cut effects of ZD1839, C225 or their combination on
PAKT (Figure 3B). ZD1839 or C225 given alone downregulate
Pp42–44 up to 300 after serum addition; in contrast, combining
them clearly enhanced this cell division-related pathway
(Figure 3C). This observation corroborates the results on cell
proliferation and strengthens the antagonistic interaction for cell
survival between ZD1839 and C225.
The apparent antagonism between the two drugs could be
accounted for by a modification of EGFR sites. Epidermal growth
factor receptor cell quantification and EGFR ligand affinity are
depicted in Table 2 and Figure 4 for the different tested conditions.
Drugs alone led to a diminution in EGFR levels as compared to
controls, with a stronger effect for C225 as compared to ZD1839. In
contrast, the combination of the two drugs increased the cellular
expression in EGFR. This increase was observed with both EGFR
protein measurement (Figure 4) and with the specific quantifica-
tion of EGFR receptors (Table 2).
DISCUSSION
In the current search for new therapeutic targets in cancer, growth
factors and their receptors represent a field of active investigation
both at preclinical and clinical levels. The EGFR receptor is
significantly overexpressed in solid tumors and constitutes an
important target for the development of the new targeted
anticancer drugs (Baselga, 2001; Mendelsohn, 2002). There are
two different categories of compounds in the current arena of
active drugs targeting EGFR with monoclonal antibodies on the
one hand and TKIs on the other. C225 (cetuximab) is the most
clinically advanced representative drug in the family of mono-
clonal antibodies targeting EGFR (Herbst and Hong, 2002; Saltz
et al, 2004). ZD1839 (Iressa) is one of the EGFR-specific TKIs
currently under active clinical investigation (Ranson et al, 2002;
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Figure 1 Dose–effect curves of C225 alone, ZD1839 alone and their
combination on CAL33 cell line. Bars depict standard deviations from
triplicate experiments.
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C225−ZD1839 combination on CAL39 cells
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Figure 2 Dose–effect curves of C225 alone, ZD1839 alone and their
combination on CAL39 cell line. Bars depict standard deviations from
triplicate experiments.
Table 1 Combined cytotoxic effects with C225 and ZD1839
CI value for the combination between C225 andZD1839
b
Cell line R value for the combination between C225andZD1839
a 50 75 90
CAL33 1.770.6 1.570.05 1.870.7 2.672.3
CAL39 3.371.5
c 1.3670.2 2.772
aR, mean7s.d. values from three separate experiments.
bCI mean7s.d. values from three separate experiments for 50, 75, 90% cytotoxic effects.
cCalculation not feasible.
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sFukuoka et al, 2003). Although C225 and ZD1839 target the same
EGFR receptor, there are some differences between these two
drugs. First, they interact with different domains of the EGFR
protein with C225 recognising the extracellular part of EGFR and
ZD1839 acting on the intracellular ATP pocket of the tyr kinase
entity. As the biological activity of ZD1839 may be attributed to its
antityr kinase action, the exact mechanism of action of C225 is
perhaps more complex. Its activity is partly related to its
interaction with the EGFR and partly related to antibody-directed
cell cytotoxicity as described for Herceptin (Clynes et al, 2000).
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Figure 3 (A) Effects of C225, ZD1839 and their combination on PARP cleavage after the end of drug exposure and before serum input on CAL33 cell
line. Bars depict standard deviations from triplicate experiments. (B) Effects of C225, ZD1839 and their combination on PAKT expression induced by serum
input on CAL33 cell line. Bars depict standard deviations from triplicate experiments. (C) Effects of C225 and ZD1839 on the P-p42–44 expression
induced by serum input on CAL33 cell line. Bars depict standard deviations from triplicate experiments.
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sC225 is administered by i.v. injections, while ZD1839 is an oral
drug. The pharmacodynamics of the two drugs, although super-
imposable regarding adverse cutaneous effects, differ as regards
digestive toxicity, which is mainly observed during ZD1839
treatment (Thomas and Grandis, 2004). Of interest, the two drugs
may possess different resistance mechanisms, since it has recently
been reported that the clinical efficacy of Iressa in lung cancer
patients was related to the presence of activating mutations located
in the domain of the ATP pocket (Lynch et al, 2004); it is not
certain that these mutations impact on the antitumour efficacy of
monoclonal antibodies. Taken together, the above-mentioned
arguments provided justification for testing the combination of
C225 and ZD1839. A recent study by Huang et al (2004) examined
the antitumour effects resulting from this dual combination more
marked tumour regressions were observed with the combination
of ZD1839 and C225 in mice bearing a human lung cancer
xenograft. Another recent study by Matar et al (2004), based on
both in vitro and in vivo data, led to similar conclusions.
In the present study, when combining data from cell survival
and those obtained by examining molecular factors, there are
strong concording arguments suggesting that the combination of
the two drugs triggers less than additive cytotoxic effects. The
studies by Huang et al (2004) and Matar et al (2004) were based on
in vitro and in vivo experiments. It must be underlined that, when
examining the different cell lines which were explored in these two
latter studies, the supra-additivity of the dual EGFR targeting was
not found in all explored cell lines; these cell lines differed
markedly between them for the EGFR content. Differences in
intrinsic EGFR tumoral expression may modulate the final impact
of the dual EGFR targeting and explain the differences between the
present conclusions and those reported by the two other groups
(Huang et al, 2004; Matar et al, 2004). In the present study, the
infra-additive impact on cell survival was sustained by the changes
in cleaved PARP, a faithful molecular indicator of apoptotic
process, showing that C225-ZD1839 caused less apoptosis than
ZD1839 alone. Further drug-related specific molecular examina-
tion indicated that, following drug exposure and cell stimulation
by the medium, there was very little activation of the Map kinase
pathway (changes in P-p42–44) following cell treatment by either
drug, contrasting with the sharp increase in P-p42–44 noted after
the combined application to ZD1839 plus C225 (Figure 3c). This
observation could plausibly be explained by the fact that C225,
markedly, and ZD1839, slightly, downregulate EGFR expression
(Figure 4), while their combination has a marked opposite effect
with an overexpression of EGFR. Importantly, both analytical
methods (Western blot and ligand-binding assay) concurred to
highlight the upregulation of EGFR when administering the drug
combination. This means that the increase in EGFR involves active
and functional receptors (data from Scatchard analysis). The
underlying mechanism of this upregulation of the EGFR target
produced by the two drugs is not easy to elucidate. Receptor
downregulation has been studied most effectively for tyrosine
kinase receptor and especially for EGFR (Waterman and Yarden,
2001). Thus, subsequent to its ubiquitination, EGFR is subject to
lysosomal degradation (Citri et al, 2002). It has been reported that
the binding of the natural ligand to EGFR results in a
conformational change in the external domain of the receptor
(Greenfield et al, 1989), which could be crucial to the ligand-
induced internalisation of the receptor (Opresko et al, 1995). There
is thus a ligand-controlled turnover in the expression of EGFR,
which could be deregulated in the combined presence of C225 and
ZD1839. Recently, the identification of proteins p70 and Clip 4 was
reported (Kowanetz et al, 2004); these proteins inhibit endocytosis
of EGFR and interact with Cbl, a ubiquitin ligase which plays a
critical role in EGFR endosomal degradation (Ettenberg et al,
2001). It is possible that the combined presence of C225 and
ZD1839 may alter the interaction of Cbl with EGFR by a
conformational change induced in EGFR.
Table 2 EGFR quantification (Scatchard analysis)
Control ZD1839 (2 10
 6 M) C225 (10
 9 M) ZD1839+C225
N high-affinity receptors 43.1270.8 50.1970.93 39.8570.74 88.271.63
KD 0.3170.12 0.2270.11 0.2270.15 0.4870.07
Mean7s.d. for EGFR numbers N (fmol per well) and dissociation constants KD values (nM) determined using Scatchard plot analysis. See details for experimental conditions in the
Materials and Methods section.
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Figure 4 Effects of C225, ZD1839 and their combination on EGFR expression on CAL33 cell line. Bars depict standard deviations from triplicate
experiments.
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sIn conclusion, the present study provides concording pre-
clinical data based on cell toxicity and molecular pharmacology.
These data suggest that new and tempting treatment strategies on
the EGFR target consisting in a double hit with a monoclonal
antibody and a tyr kinase inhibitor must be considered with
caution.
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